Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lymphocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm

Cancer Family

Lymphocytic Neoplasm

CI-CAN-00000223Explore in graph →

HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items

NCIt: C7065

Overview
Statistics
Survival
Genomics38
Variants & evidence345
Drugs51
Trials12949
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (380)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Oct 1, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 380 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.
Can Huang, Xuyan Zhang, Yuanyin Teng et al. · Int J Nanomedicine · Jan 1, 2026 · PMID 42703556 · candidate dictionary pubmed
Celiac Disease Emerging After ASCT in Multiple Myeloma: A Rare Diagnostic Intersection and Literature Review.
Mais Musleh, Mahmoud Alhamadeh Alswij, Qossay Alhusein · Case Rep Hematol · Jan 1, 2026 · PMID 42688865 · candidate dictionary pubmed
Primary ocular-adnexal non-Hodgkin Lymphoma in a Peruvian cohort: An 18-year experience.
Renato Luque-Benavides, Gabriel De la Cruz Ku, Bryan Valcarcel et al. · PLoS One · Jan 1, 2026 · PMID 42640970 · candidate dictionary pubmed
Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy.
Donna Liao, Mahmood Aminilari, Xiang Y Ye et al. · Pract Radiat Oncol · Jan 1, 2026 · PMID 41765363 · candidate dictionary pubmed
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.
Liming Yu, Changnian Li, Dadong Guo et al. · Front Immunol · Jan 1, 2026 · PMID 42746158 · candidate dictionary pubmed
Rituximab-Conjugated DART Nanoformulation for CD20-Targeted Drug Delivery in Non-Hodgkin Lymphoma.
Md Musavvir Mahmud, Byoungjae Kong, Daiheon Lee et al. · Int J Nanomedicine · Jan 1, 2026 · PMID 42764913 · candidate dictionary pubmed

Showing 176–200 of 380 publications

← Previous
1
…
7
8
9
…
16
Next →

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

· Blood · 2016 · PMID 27069254 · validated civic_curation pubmed

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed

Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.

· J Clin Oncol · 2018 · PMID 30044693 · validated civic_curation pubmed

The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis.

· Cancer Biomark · 2014 · PMID 25335741 · validated civic_curation pubmed

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

· Leukemia · 2022 · PMID 35732829 · validated civic_curation pubmed

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

· J Clin Oncol · 2017 · PMID 28787259 · validated civic_curation pubmed

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

· N Engl J Med · 2014 · PMID 25207766 · validated civic_curation pubmed

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

· Lancet Oncol · 2020 · PMID 33035457 · validated civic_curation pubmed

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

· Oncotarget · 2017 · PMID 27894077 · validated civic_curation pubmed

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

· Lancet Oncol · 2018 · PMID 29650362 · validated civic_curation pubmed

TP53 mutation and survival in chronic lymphocytic leukemia.

· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

· N Engl J Med · 2014 · PMID 24869598 · validated civic_curation pubmed

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

· Nat Genet · 2019 · PMID 30643249 · validated civic_curation pubmed

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

· Blood · 2005 · PMID 16081687 · validated civic_curation pubmed

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.

· Nat Rev Cancer · 2007 · PMID 17891190 · validated civic_curation pubmed

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

· N Engl J Med · 2002 · PMID 12075054 · validated civic_curation pubmed

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

· Blood · 1997 · PMID 9207459 · validated civic_curation pubmed

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

· Nat Genet · 2010 · PMID 20081860 · validated civic_curation pubmed